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Abstract
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Plant extracts continue to represent an untapped source of renewable therapeutic compounds for
the treatment and prevention of illnesses including chronic metabolic disorders. With the increase
in worldwide obesity and its related morbidities, the need for identifying safe and effective
treatments is also rising. As such, use of primary human adipose-derived stem cells represents a
physiologically relevant cell system to screen for bioactive agents in the prevention and treatment
of obesity and its related complications. By using these cells in a primary screen, the risk and cost
of identifying artifacts due to interspecies variation and immortalized cell lines is eliminated. We
demonstrate that these cells can be formatted into 384-well high throughput screens to rapidly
identify botanical extracts that affect lipogenesis and lipolysis. Additionally, counterscreening
with human primary stem cells from distinct adipose depots can be routinely performed to identify
tissue specific responses. In our study, over 500 botanical extracts were screened and 16 (2.7%)
were found to affect lipogenesis and 4 (0.7%) affected lipolysis.
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1. Introduction
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The prevalence of obesity, metabolic syndrome, diabetes, and their associated comorbidities have increased significantly across the world over the recent past. As such, it is
imperative we implement successful and viable strategies in order to address the global
epidemic. In this regard, and in an historical perspective, extracts from plants, i.e. botanicals,
have proven to be a rich resource for the discovery of therapeutic compounds and the
sources of many current medicinal drugs. Throughout the world, traditional cultures have
identified specific plant species for the treatment of multiple disorders, including the
metabolic syndrome and diabetes. In particular, plant extracts proposed to contain effective
“bioactives” are marketed routinely as therapeutic agents for metabolic syndrome and
diabetes, often with limited understanding of mechanism or proof of efficacy. Recently, the
World Health Organization and the NIH have supported international efforts to develop
comprehensive libraries of botanical extracts for therapeutic drug discovery. Studies have
begun to screen these libraries for candidate molecules directed towards the prevention and
treatment of the metabolic syndrome using cell based in vitro assays.
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Given the importance of insulin resistance in peripheral tissues such as adipose tissue and
muscle in the etiology of metabolic syndrome and progression to Type 2 diabetes, both
adipocyte and skeletal muscle cell lines have been employed in these studies. In most
analyses of adipocytes, investigators have chosen to use the 3T3-L1 murine pre-adipocyte
cell line. This in vitro model of adipogenesis is characterized by a homogeneous
morphology and a robust lipogenic and lipolytic response to known agonists and
antagonists. However, since the 3T3-L1 cell line is of murine origin, its utility as a drug
discovery tool for eventual human conditions has been questioned due to inter-species
variations. A number of laboratories, including those in the pharmaceutical industry, have
begun to employ primary human adipose-derived stromal/stem cells (ASCs) as an
alternative in vitro model for adipocyte differentiation and function. The ASC can be
derived from many adipose depots in human subjects, including subcutaneous and omental/
visceral tissue. There is a growing body of literature indicating that the metabolic function
and drug response of adipocytes in these depots is distinct. This has potential implications
with respect to the pathology, diagnosis, and treatment of metabolic syndrome and diabetes
for the human condition. The current study reports the use of both primary human
subcutaneous- and visceral-derived ASCs to screen a library of botanical extracts for both
lipogenic and lipolytic agonists and antagonists. These preliminary studies have the potential
to yield novel pharmaceuticals of plant origin for the treatment or prevention of metabolic
syndrome.
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2. Materials and methods
2.1. Chemicals
2.1.1. Botanical Extract Library—The source of plant extracts were prepared and
obtained from the John S. McIlhenny Laboratory of Botanical Research as part of the NIH
funded Center for the study of Botanicals and Metabolic Syndrome. The extracts were
originally obtained as part of the International Cooperative Biodiversity Group (ICBG)
program. Field-collected plant samples were prepared by air drying and extraction with 80%
ethanol (1:5 w/v) three times, infused each time for 24 h and evaporated in a rotary
evaporator. The obtained extracts were dried under vacuum and stored in amber glass vials
at −20 °C. The yield of air dried extract as the percent weight of the dried plant tissue varied
among the tested samples based on the plant part used. Before tests, concentrates were
dissolved by sonication in DMSO for a final concentration of 20 mg/mL.
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2.1.2. Chemicals and reagents—Type I collagenase was obtained from Worthington
Biochemical (Lakewood, NJ). Bovine serum albumin (BSA), dexamethasone, biotin,
pantothenate, isoproterenol, and isobutyl methylxanthine (IBMX) were purchased from
Sigma (St Louis, MO). Human recombinant insulin was obtained from MP Biomedicals
(Solon, OH). The fetal bovine serum, Dulbecco modified Eagle’s medium (DMEM),
phosphate-buffered saline (PBS), and Ham’s F-12 nutrient broth were from Zen-Bio (RTP,
NC). Tumor Necrosis Factor alpha was from Roche Diagnostics (Indianapolis, IN). All
tissue culture flasks and plates were obtained from Corning (Corning, NY).
2.2. Preparation and culture of primary ASC from subcutaneous and visceral depots
2.2.1. Isolation of human primary ASCs from subcutaneous and omental
depots—Human adipose tissue samples were procured from consenting donors undergoing
elective surgeries under IRB approved protocols. Subcutaneous and omental adipose tissue
was from surgical waste material derived from subcutaneous lipoaspirate or omentum tissue.
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Human ASCs were isolated from lipoaspirate or omental waste tissue as previously
described. Adipose tissue was extensively washed with PBS prior to processing. Omental
tissue samples were hand-minced while washed lipoaspirate material was directly
transferred for dissolution with an equal volume of Krebs Ringer buffer containing 0.1%
collagenase and 1% BSA. Following a 15–45 minute incubation at 37 °C, floating primary
adipocytes and most of the collagenase buffer were removed and PBS was added. The
remaining stromal vascular cell suspension was subjected to centrifugation for 5 minutes at
300 × g and the resulting cell pellet washed several times with PBS. Finally the cell pellet
was suspended in preadipocyte medium (PM-1, Zen-Bio) and plated in a culture flask for
expansion. ASCs were subcultured prior to reaching confluence and plated at a density of
1.4 million cells per T-225 flask (6,300 cells/cm2) for further expansion in PM-1 containing
epidermal growth factor (EGF) and fibroblast growth factor (FGF).
2.2.2. Preparation of subcutaneous and omental ASC super-lots—Mixed patient
lots of either subcutaneous or omental ASCs were prepared from cryopreserved ASCs
derived from 4–6 donor lots each. The subcutaneous super-lot was derived from 6 female
donors with an average age of 40 ± 3.3 (S.E.) and average BMI of 27.9 ± 0.6. The omental
super-lot was derived from 4 female donors with an average age of 40 ± 3.8 (S.E.) and
average BMI of 45.6 ± 4.9. Equal numbers of passage 1 ASCs were combined in
preadipocyte medium and plated for expansion at a density of 2.2 million cells per chamber
(3,500 cells/cm2) in CellSTACK chambers (Corning). The super-lot cells were expanded to
near confluence and harvested by trypsinization for cryopreservation and later use.
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To ensure the quality of the prepared cell super-lots, both the omental and subcutaneous lots
were tested for differentiation and lipolytic response. Both lots met the required cutoff
values for triglyceride accumulation and free fatty acid (FFA) release under standard
differentiation procedures. Cell surface markers for both lots of ASCs were confirmed using
flow cytometry and antibodies to positive markers (CD29, CD44, and CD105) and negative
markers (CD14, CD31, and CD45).
2.3. Screen botanical extracts for human adipocyte lipolysis
Mature adipocytes in clear bottom 384-well plates were prepared by seeding ASCs at a
density of 6,000 cells/well and differentiating them to adipocytes by adding differentiation
medium (DM-2, Zen-Bio) for 7 days. After differentiation, the medium was partially
replaced with adipocyte medium (AM-1, Zen-Bio) and the cells incubated for a further 7
days at 37 °C with 5% CO2. This procedure results in greater than 80% adipocyte
differentiation. Medium was aspirated and the cells washed twice with 50 μl PBS using a

J Nutr Biochem. Author manuscript; available in PMC 2013 June 01.

Buehrer et al.

Page 4

NIH-PA Author Manuscript

cell washer (ELx-405 Select CW, BioTek) prior to adding 25 μl of assay buffer to each well.
Botanical extracts were diluted in a two step process by using a Matrix PlateMate 2×3
(ThermoScientific), first a 50-fold dilution into assay buffer was performed, followed by a
similar 10-fold dilution. 25 μl of the 500-fold dilutions were added to the assay plates in
quadruplicate for a final dilution of 1000-fold (20 μg/ml). Isoproterenol (100nM) and
DMSO (0.1%) were added to quadruplicate wells on every plate and served as the positive
and negative controls, respectively. Cells and extracts were incubated for 4 hours at 37 °C
with 5% CO2 to accumulate free fatty acid in the conditioned assay buffer.
For follow-up experiments in 96-well plates, preadipocytes were seeded at a density of
13,000 cells/well and differentiated as described above. Cells were washed twice with PBS
and treated with extracts in a final volume of 100 μl of assay buffer for 4 hours.
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2.3.1. Measuring fatty acid release in human cultured adipocytes—Free fatty
acids released into the conditioned assay buffer were quantified using Lipolysis Assay Kit
reagents (Zen-Bio, Inc.). For the initial screen, 15 μl of conditioned assay buffer was
removed from each well and transferred to new 384-well plate for determination of fatty
acid release. 50 μl of FFA solution A was added to 15 μl of conditioned assay buffer and
incubated at 37 °C for 10 minutes. 25 μl of FFA solution B was added to each well and
incubated for an additional 10 minutes at 37 °C. Total Free fatty acids released were
determined by measuring the optical density at 540 nm and comparison to a standard curve
ranging from 1.5 to 333 μM. Quadruplicate values were averaged and standard deviations
were used to determine statistical differences between controls. Follow up assays were
performed in 96-well plates essentially as described but with 30 μl of conditioned assay
buffer, 100 μl FFA solution A and 50 μl FFA solution B.
To determine if positive values resulted from extract interference with the assay reagents,
we performed fatty acid assays using extracts diluted into assay buffer without exposure to
cells. If the resulting value was above 10 μM, it was concluded that the extract interfered
with the assay.
2.4. Screen botanical extracts for lipogenic effects in human adipocytes
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ASCs were seeded at 6,000 cells/well in clear bottom 384-well plates using PM-1. The next
day a 40% mixture of DM-2 and PM-1 was added and incubated for 7 days at 37 °C with
5% CO2. 4 wells were given 100% DM-2 to serve as a positive control. An additional 4
wells were given PM-1 to serve as an uninduced control. Botanical extracts were added on
day 7 through a two step dilution process in AM-1 to give a 50 μg/ml final concentration.
0.25% DMSO was added to 4 wells to serve as a vehicle control and 10 ng/ml TNFα served
as a positive control of inhibition. The cells and extracts were incubated at 37 °C with 5%
CO2 for an additional 7 days prior to quantifying total accumulate triglyceride.
2.4.1. Triglyceride measurement in subcutaneous and omental adipocytes—
The total accumulated triglyceride was determined using Total Triglyceride Kit reagents
(Zen-Bio, Inc.). The medium was aspirated and the cells were washed once with 50 μl Wash
Buffer using an automated cell washer (BioTek). 5 μl of Lysis Buffer was added to each
well and cells were incubated at 37 °C for 20 minutes to complete the cellular lysis. 45 μl of
Wash Buffer was added to each well before adding 6.7 μl Reagent B (lipase) and incubating
for an additional 2 hours at 37 °C. 12.5 μl of each lipase treated sample was transferred to a
new 384-well plate containing 12.5 μl Wash Buffer. An equal volume of Glycerol Reagent
A (25 μl) was added to each well and incubated for 15 minutes at room temperature.
Glycerol content was determined by measuring the optical density at 540 nm and comparing
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the values to a glycerol standard curve. There is a 1:1 molar ratio between the amount of
glycerol detected and cellular triglyceride content.
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Treatments and assays performed in 96-well plates followed a similar protocol, but the
volumes were adjusted for the larger plate format. Preadipocytes were seeded at 13,000 cells
per well prior to differentiation and extract treatment in 150 μl final volume. Volumes were
changed to 15 μl Lysis buffer, 135 μl Wash buffer and 20 μl of Reagent B. 10 μl of each
sample was diluted into 40 μl of Wash buffer and 50 μl of Reagent A added to initiate
quantification of glycerol.
2.5. Cytotoxicity analysis of botanical extracts
Extract induced cytotoxicity was assessed in the 384-well format using conditions for the
lipogenic assay. Instead of performing the triglyceride assay, 25 μl of conditioned medium
was removed and 5 μl of Cell Titer Blue reagent (Promega) added to each well. Cells and
reagent were incubated at 37 °C in a humidified 5% CO2 incubator for 2 hours. The
absorbance a 570 nm was measured for each well and that from the reference wavelength
(600 nm) subtracted. The background value (OD570–OD600) from wells without cells was
subtracted from each value to determine the extract induced change in absorbance.
Cytotoxicity was reflected by a decrease in the (OD570–OD600) absorbance value. 0.1%
Triton X-100 served as a positive control for cytotoxicity.
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2.6. Statistics
For the screen results, quadruplicate values were averaged and the standard deviation for
each treatment determined. Values are displayed based on total cell number seeded per well.
Significant differences from control values were determined using a paired Student’s t-test
with p ≤ 0.05 cutoff. Cutoff values for an active extract identified in the primary screen were
established based on being more than 3 standard deviations from the control mean. The
screening statistic, Z′, was determined for each assay according to Zhang et al based on the
means and standard deviations of the positive and negative controls using the following
, where SD1 is positive control standard deviation; SD2 is
equation:
negative control standard deviation; μ1 is positive control mean; μ2 is negative control
mean. EC50 and IC50 values were determined by fitting dose response data to a four
parameter logistic equation using GraphPad Prism software (GraphPad Software, Inc.).

3. Results
NIH-PA Author Manuscript

A collection of 580 botanical extracts derived from Central Asian plants were tested for their
effects on human adipocyte lipolysis and lipogenesis following the outline depicted in
Figure 1. The extracts are unfractionated botanical mixtures and will serve as starting points
to identify active components. The complexity of the mixtures dictated the use of a
maximum concentration allowed by the assays to identify active extracts. High throughput
primary human cell screening assays were developed for lipolysis and lipogenesis to identify
both inhibitors and inducers in a single screen.
3.1. Identification of botanical extracts with lipolytic inductive and suppressive properties
in subcutaneous adipocytes
All botanical extracts were examined for their acute lipolytic effect on human subcutaneous
adipocytes in culture. To maximize signal to background and minimize the effect of FFA
reuptake, the cells were exposed to the extracts for four hours prior to measuring free fatty
acid release into the assay medium. The extract concentration was limited to 20 μg/ml to
keep DMSO at or below 0.1% in the assay. Figure 2 shows the effects of each extract on
J Nutr Biochem. Author manuscript; available in PMC 2013 June 01.
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FFA release as percent of the un-stimulated control (0.1% DMSO). Most of the extracts had
little effect, clustering around the vehicle control (100%). However, 15 extracts were chosen
for follow up studies because their activity was significantly above the screening cutoff
value (3 standard deviations above the mean). The Z′ value (see Methods) for this screen
was 0.503, an acceptable value for initial screening.
3.2. Partial lipolysis screen of botanical extracts in human omental cultured adipocytes
Omental adiposity is linked to diabetes and metabolic disorders, suggesting that a screen
using primary human omental adipocytes should be the most physiologically relevant
system to identify novel actives. To determine the utility and overlap of a 384-well based
omental adipocyte screen, half of the extracts were screened for their acute lipolytic effects
using human omental adipocytes. After four hours of extract exposure, the amount of FFA
released in the culture medium was determined. A similar number of active extracts were
found using omental adipose derived cells as shown in Figure 3. Considerable overlap of
active extracts was found in the omental screen and further characterization of the primary
screen active extracts was performed. The Z′ value for the omental screen was determined
to be 0.514, on par with the primary subcutaneous adipocyte screen.
3.3. Confirmation and dose dependence of lipolytic extracts in both subcutaneous and
omental cells
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Fifteen extracts (2.6%) from the subcutaneous cell and 8 extracts (2.7%) from the omental
cell screens showed an increase in lipolysis and were selected to determine if their primary
activity could be confirmed. Human adipocytes were treated with 20 and 50 μg/ml of the
botanical extracts for 4 hours and the amount of FFA released was determined. Additionally,
the extracts were tested to determine if they interfered with the assay reagents to give a false
positive signal by incubating them with the reagents alone. Only four of the 23 extracts
selected for additional testing had their initial activity confirmed and were not observed to
significantly interfere with the assay reagents or induce cytotoxicity (data not shown). The 4
identified extracts were KPL_00107E1, KPL_00248E12, KPL_00120E1, and
UPL_00042E9. .
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The four extracts were serially diluted to determine their dose response effect on adipocyte
lipolysis in both subcutaneous and omental cells. Extract KPL_00120E1 displayed the
largest increase in lipolysis and lowest EC50 in both subcutaneous and omental adipocytes
(Table 1). The remaining extracts displayed dose dependent increases in lipolysis in both
cell types compared to the vehicle control. Only KPL_00120E1 and KPL_00248E12
displayed EC50 values below 15 μg/ml and robust lipolysis without cytotoxicity. Three
extracts were identified from the primary subcutaneous cell screen to inhibit basal lipolysis
without inducing cytotoxicity; however, these extracts did not confirm their activity in
follow up assays.
3.4. Identification of botanical extracts with lipogenic properties using human primary
subcutaneous preadipocytes
The same 580 botanical extracts were tested for their effects on human subcutaneous
adipocyte lipogenesis using partially differentiated adipocytes. Extracts were added to 1
week old partially differentiated ASCs and incubated with cells for 7 days. This second 7
day period is when differentiated adipocytes accumulate large amounts of triglyceride
through lipogenesis. Extract concentrations of 50 μg/ml were used to maximize the response
while limiting the cytotoxic effect of DMSO (0.25%). 10 ng/ml TNFα served as a positive
control, inhibiting lipogenesis and triglyceride accumulation by 65% without cytotoxicity.
Lipogenesis and cytotoxcity were determined for each extract in separate cell-based screens.
Figure 4 shows the combined results of the two screens displaying triglyceride levels for
J Nutr Biochem. Author manuscript; available in PMC 2013 June 01.
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both cytotoxic and noncytotoxic extracts. The lipogenesis screen gave a Z′=0.61. 44 extracts
(7.6%) actively inhibited lipogenesis without inducing cytotoxicity and 2 induced
lipogenesis. 14 of the initial actives from the primary screen were confirmed in a secondary
inhibition assay and were retested in a dose response in subcutaneous and omental cells.
Maximal inhibition of lipogenesis and induced cytotoxicity effects (and their IC50
concentrations) are shown for eight extracts in Table 2. Three extracts (KPL_00752E12,
KPL_00752E7, and KPL_00752E4) displayed dose response inhibition of lipogenesis that
was clearly separated from cytotoxicity effects. The two extracts that enhanced lipogenesis
appear to contain free fatty acids and may have increased lipogenesis by increasing
exogenous lipid concentration in the treatment medium.

4. Discussion
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High throughput screening is the mainstay of drug discovery often relying on well-defined
targets using miniaturized in vitro assays to allow rapid testing of hundreds of thousands of
compounds. Cell-based activity assays also provide a robust screening system presenting the
drug target in a more relevant context. These cell-based assay systems are typically
constructed to enhance screening parameters while sacrificing the normal biological context
of the target. One way to overcome this drawback is to use primary cells containing the
target of interest. With recent advancements in human primary cell isolation and
propagation, large numbers of high quality cells are readily available for drug discovery.
The current study demonstrates the potential of primary human ASC cultures to be used in
primary compound or botanical screens. Specifically, we demonstrate that both
undifferentiated and differentiated adipocyte cultures of primary human ASCs derived from
subcutaneous and visceral/omental adipose depots can be used to efficiently screen botanical
extracts in vitro. This indicates that the human primary ASC cultures can be adapted to a
384 well plate format and used as a robust alternative to murine pre-adipocyte cell lines such
as 3T3-L1. Additionally, the use of a mixed donor lot can generate the billions of cells
required for large screens and greatly reduce cell costs while averaging out the donor-todonor variability inherent in human primary cells.
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While botanical extracts provide an available source of novel bioactive molecules, the use of
unfractionated mixtures complicates primary screening. We have taken a systems approach
by using human primary cell based assays to identify active extracts. This limits the bias of
pre-selecting the target, however it adds complications of its own including possible
cytotoxicity, cell impermeability, and metabolic activation of the extracts. Successful
identification of active crude extracts requires a robust assay and can test the limits of a
primary screen. Our results suggest human primary ASCs provide a relevant and robust
primary cell based screening system. The primary and secondary screens of over 500
botanical extracts identified unique subsets with pro-lipolytic and anti-lipogenic activities
that may eventually be useful in treating metabolic disorders.
The plant specimen collection used in this study contains a comprehensive sampling of
Central Asia’s (Kazakhstan, Kyrgyzstan, Tajikistan and Uzbekistan) plant biodiversity.
Emphasis was placed on endemic plants and plants that either belong to families known for
high natural product production or are known as local medicinal plants. In addition, plants of
the same species were collected from various extreme environmental conditions under the
premise that plants exposed to different stresses often contain different inducible natural
products with different bioactivities. All collected samples are vouchered as herbarium
specimens.
Two extracts with relatively potent lipolytic effects were identified in our screen and are
derived from A. soongaricum, a relative of wolfsbane, and C. ochrolepidium, a relative of
J Nutr Biochem. Author manuscript; available in PMC 2013 June 01.
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the common garden thistle. This Aconitum species is known to contain potent alkaloids with
bioactive properties including immunological and antiarrhythmia activities. Recently, a root
extract from another Aconitum species, A. carmichaeli Debeaux (Ranunculaceae), was
found to have profound effects on the metabolic function of brown adipose tissue (BAT) in
cold-stressed mice. The authors demonstrated that the extract enhanced UCP-1 gene
expression and maintained the animal’s core body temperature by increasing brown adipose
tissue at the expense of white adipose. A similar induction of lipolysis to liberate fatty acids
for fuel consumption may be occurring in the adipocytes treated with the A. soongaricum
extract (KPL_00120E1). Likewise, the Cirsium ochrolepidium Juz. extract increased
lipolysis in both subcutaneous and omental adipocytes (KPL_00248E12), however, extracts
of this particular species have not been studied extensively. A different Cirsium species, C.
oligophyllum, has been shown to contain bioactive components that activate lipolysis in
cultured rat adipocytes. Additionally, oral administration of the extract reduced fat mass and
overall body weight in the rats, increasing UCP-1 gene expression both in white adipose and
brown adipose tissue. It is highly likely that a similar effect was identified in our screen
from the Cirsium extract that we tested. The identification of these extracts from genera with
known adipocyte activities further validates the utility of this screening system.
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Three extracts from Acer negundo L. were found to have potent anti-lipogenic properties
which did not represent aspects of cytotoxcity. These extracts were derived from different
parts of the plant, with the leaf and above ground extracts showing more potency than the
stem and twig extract. This species of maple has been found to contain flavonoids and other
potentially bioactive compounds, however, extracts from A. negundo have not been studied
for their effects on obesity. Another species of maple, A. tegmentosum, has been used in
Korean traditional medicine to treat hepatic disorders including cirrhosis, hepatitis, and
cancer. Some of these effects are attributed to the anti-inflammatory and antioxidant
activities of some of the flavonoids found in the extracts. It seems likely that the A. negundo
extracts may possess similar flavonoids that may be responsible for its ability to reduce
lipogenesis. Several flavonoids have been found to inhibit lipogenesis in adipocytes and
other cells through a variety of mechanisms including inhibiting fatty acid synthase or
nuclear receptors. While we have not identified the active components of these extracts,
there is reason to suspect similar bioactive components already known to inhibit adipocyte
lipogenesis.
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Subcutaneous and visceral adipose depots differ with respect to their cellular composition
and expression of adipokines and pro-inflammatory growth factors. Their relative abundance
is believed to play a contributory role to the pathogenesis of insulin resistance and the
metabolic syndrome. Increased visceral adiposity, as compared to subcutaneous adiposity,
has been correlated with the onset and severity of hyperglycemia, hypertriglyceridemia, and
related co-morbidities of the metabolic syndrome. For these reasons, focusing on the use of
visceral/omental derived rather than subcutaneous derived ASCs may have particular
advantages as far as determining more precise pathophysiologic roles and may be more
amenable for further development of drug discovery and botanical extract screening. In the
current study, visceral ASCs were used in a limited primary screen and as a secondary
counter-screen, however, they can be easily expanded and formatted for use in much larger
primary screens. While their lipolytic responses were very similar, the lipogenic responses
between omental and subcutaneous ASCs varied; however, the same trends were identified
in both cell types.
Botanical extracts offer advantages and challenges both as adjunctive therapies and as a
source of future pharmaceuticals. Plants serve as a rich source of diverse chemical
compounds, i.e. bioactives, which, theoretically, can be extracted with appropriate methods,
thereby reducing the cost of both discovery and manufacture. Coupling renewable botanical
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extracts with human primary cell screening technology represents a rapid and economical
method to identify natural products that can become therapeutics.
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Figure 1.

Diagram of screening paradigm
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Figure 2.
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Botanical extract lipolysis screen results using subcutaneous adipocytes. 580 botanical
extracts were tested for their ability to induce fatty acid release. Values are shown as percent
of the vehicle control (0.1% DMSO). The solid line represents the vehicle control value for
fatty acid release (100%). The dashed line represents the screening cutoff value for active
extracts: the overall mean +/− three times the standard deviation. Extracts are represented by
numerical progression on the x-axis. The y-axis is a log scale to contain the data range.
Values are the mean of 4 replicates.
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Figure 3.
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Partial lipolysis screen results using omental adipocytes. A subset of the extracts were tested
for their ability to induce fatty acid release in human omental adipocytes. Values and lines
are as described for figure 2. The y-axis is linear. Values are the mean of 4 replicates.
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Figure 4.
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Combined results of the lipogenic and cytotoxic effects of the botanical extracts. Values are
displayed as percent of vehicle control for triglyceride accumulation. Extracts that showed
cytotoxicity are represented by an “X”, nontoxic extracts are represented by a filled circle.
Values are the mean of 4 replicates.
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